Taxol And Taxotere Both Cleared For Routine Use After Bristol Appeal To U.K.
Both Bristol-Myers Squibb's Taxol and Aventis' Taxotere have been recommended for routine use by U.K.' s National Institute for Clinical Excellence for advanced second-line breast cancer treatment, following a successful appeal by Bristol.
You may also be interested in...
Teva is expecting U.K. licensure of its multiple sclerosis drug Copaxone (glatiramer) in July for reduction in frequency of relapse in relapsing/remitting MS, the company indicated.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011